New hope for rare, Tough-to-Treat lung cancer
Disease control
Not yet recruiting
This study is testing the safety and effectiveness of combining two drugs, lurbinectedin and osimertinib, for a rare and aggressive type of lung cancer called transformed small cell lung cancer. It will involve about 16 adults whose cancer started as one type and changed into thi…
Phase: PHASE1, PHASE2 • Sponsor: Misty Shields • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC